<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052416</url>
  </required_header>
  <id_info>
    <org_study_id>BIDMC-W-01-0384-FB</org_study_id>
    <secondary_id>CDR0000258419</secondary_id>
    <secondary_id>NEDH-W-01-0384-FB</secondary_id>
    <secondary_id>BIDMC-2001-P-001950</secondary_id>
    <secondary_id>NCI-V02-1714</secondary_id>
    <nct_id>NCT00052416</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.

      PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who
      have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility, in terms of toxicity and patient compliance, of thalidomide
           in patients with asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic
           leukemia.

        -  Determine the event-free and progression-free survival of patients treated with this
           drug.

        -  Determine disease response and time to next treatment in patients treated with this
           drug.

        -  Determine the quality of life of patients treated with this drug.

      OUTLINE: Patients receive oral thalidomide once daily. Treatment continues for 18 months in
      the absence of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, monthly during study, and at the end of the study.

      PROJECTED ACCRUAL: A total of 30-36 patients will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed indolent lymphoma or leukemia of one of the following
             subtypes:

               -  Chronic lymphocytic leukemia

               -  Follicular center lymphoma (grade I or II)

               -  Lymphoplasmacytic lymphoma

               -  Marginal zone lymphoma (nodal, extranodal, or splenic)

               -  Small lymphocytic lymphoma

               -  Waldenstrom's macroglobulinemia

          -  Any stage of disease allowed

          -  No hairy cell leukemia

          -  No T-cell lymphomas

          -  No prior treatment for lymphoma/leukemia

          -  Considered appropriate for expectant management

               -  Must not require cytotoxic therapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Hemoglobin greater than 10.0 g/dL

          -  Platelet count greater than 75,000/mm^3

        Hepatic

          -  Bilirubin no greater than 2 times normal

          -  AST and ALT no greater than 2 times normal

        Renal

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular

          -  No uncontrolled congestive heart failure

          -  No New York Heart Association class III or IV heart disease

          -  No unstable coronary artery disease

          -  No myocardial infarction in the past 6 months

          -  No serious or uncontrolled arrhythmias

          -  No history of thromboembolic disease

        Pulmonary

          -  No asthma or chronic obstructive pulmonary disease requiring the use of home oxygen or
             frequent oral steroids (prednisone greater than 20 mg per day for 5 days within the
             past 3 months)

        Other

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Not planning to become pregnant in the next 2 years

          -  Fertile female patients must use 1 highly effective method and 1 additional effective
             method of contraception for 1 month prior to, during, and for 1 month after study
             participation

          -  Male patients must use effective barrier contraception during and for 1 month after
             study participation

          -  Willing and able to participate in the S.T.E.P.S. (System for Thalidomide Education
             and Prescribing Safety) program

          -  No contraindications to meeting the requirements of the S.T.E.P.S. program

          -  No other prior malignancy except curatively treated non-melanoma skin cancer or
             carcinoma in situ of the cervix

          -  No peripheral neuropathy

          -  No poorly controlled diabetes defined by either of the following:

               -  Glycosylated hemoglobin greater than 8.0 g/dL

               -  Known end organ disease (i.e., nephropathy, retinopathy, or neuropathy)

          -  No other concurrent illness that would preclude study therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Joyce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

